Neurocrine Biosciences, Inc. (NBIX)
$2.13
-0.02 (-0.94%)
| CAPS Rating |
|
|---|---|
| Open | $0.00 |
| Previous Close | $2.13 |
| Daily Range | $2.05 - $2.19 |
| 52-Week Range | $2.00 - $4.25 |
| Market Cap | $83.51M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 157,086 |
| Average Daily Volume | 148,000 |
NBIX
VS S&P 500 (SPY)
This ticker is not currently Ratable.
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
NBIX Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
NBIX News and Commentary
- UPDATE 1-Neurocrine Biosciences gets funding of up to $75 mln – Reuters
- These 5 Underdogs Are No Dogs – The Motley Fool
- The FDA Stands Up Cardiome – The Motley Fool
- The Growth Stocks You Should Be Buying – The Motley Fool
- Vanda's Drug Draws a Yawn – The Motley Fool
- Following the Drugmaker Formerly Known as Neurochem – The Motley Fool
- Neurocrine on the Upswing? – The Motley Fool
- 7 Surprising Low-Rated Stocks – The Motley Fool
- Closing NBIX (Neurocrine Biosciences) underperform – Blog at The Motley Fool
- The Final Nail in Neurochem's Coffin – The Motley Fool
- Thursday's Worst Stocks in the World – The Motley Fool
- FDA Knocks Neurocrine a Knuckle Sandwich – The Motley Fool
- No Shock for Cardiome – The Motley Fool
- Wall Street's Buy List – The Motley Fool
- Welcome to the New Era of FDA Regulation – The Motley Fool
- Is the FDA Still Approving New Drugs? – The Motley Fool
- Scanning 4 Biotechs – The Motley Fool
- Making Cents in Penny Stocks – The Motley Fool
- Following the Fallen Biotech Class of 2006 – The Motley Fool
- Neurocrine Awaits Its Destiny – The Motley Fool
RSS Headlines
Fool UK
